First patients test new 'Anti-VISTA' drug for Tough-to-Treat cancers
NCT ID NCT05957081
Summary
This is the first study in people to test the safety and dosing of a new immunotherapy drug called PMC-309. It is for adults with advanced or metastatic solid tumors that have progressed despite prior treatments, including other immunotherapies. The study will test PMC-309 by itself and in combination with an existing drug, pembrolizumab, to see how well patients tolerate it and to find the right dose for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Health
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Australian Hospital Care (Pindara) PTY LTD. Trading as Pindara Private Hospital
RECRUITINGBenowa, Queensland, 4217, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ballarat Regional Integrated Cancer Centre (Grampians Health)
RECRUITINGBallarat, Victoria, 3350, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cabrini Health Limited
RECRUITINGMalvern, Victoria, 3144, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.